Phacoemulsification Combined With Intravitreal Injection of Ranibizumab Prevent Postoperative Capillary Non-perfusion Zone Progress in Non-proliferative Diabetic Retinopathy
Department of Ophthalmology, Ruijin Hospital, Affiliated Medical School, Shanghai Jiaotong University
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Zijian Yang, Dr.
- Phone Number: 88024 +862167888999
- Email: dyangzj@163.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200025
- Recruiting
- Department of Ophthalmology, Ruijin Hospital Affiliated Medical,Shanghai Jiaotong University School
-
Contact:
- Zijian Yang, Dr.
- Phone Number: 18121261251
- Email: dyangzj@163.com
-
Contact:
- Huiping Yao, Dr.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed and dated informed consent
- Commitment to follow the research procedures and cooperate with the implementation of the whole process of research
- No specific gender, 18+ years old
- Diagnosed in line with NPDR,
- Phacoemulsification combined with anti-VEGF therapy is planned
- No obvious surgical contraindications
Exclusion Criteria:
- Use of other investigational drug treatments or take part in other types of clinical studies
- Allergy to anti-VEGF drugs
- Patients with other macular and optic disc diseases
- Patients with meaningful diabetic macular edema
- Patient with surgical complications
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Cataract phacoemulsification combines Ranibizumab
0.05 ml of ranibizumab was injected into the vitreous immediately after the operation
|
intravitreal injection of Ranibizumab;
Other Names:
|
|
Active Comparator: Cataract phacoemulsification
0.05 ml of ranibizumab was injected into the vitreous immediately after the operation
|
intravitreal injection of Ranibizumab;
Other Names:
Phacoemulsification
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
capillary non-perfusion zone of non-proliferative diabetic retinopathy
Time Frame: 1 year
|
Patient were divided into two groups, the control group is phacoemulsification surgery group and the intervention group is phacoemulsification surgery combine intravitreal injection of Ranibizumab group.
Eye examination including visual acuity, intraocular pressure (IOP), fundus fluoroscopy, macular OCT examination, were taken before cataract surgery.
The anterior aqueous humor was extracted before cataract phacoemulsification in the combined operation group, and 0.05 ml of ranibizumab was injected into the vitreous immediately after the operation.
The BCVA, IOP and fundus lesions changes were observed in the two groups after operation.
Diabetic retinopathy capillary non-perfusion zone were evaluated one year after phacoemulsification surgery.
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Determination of inflammatory factors in anterior aqueous humor
Time Frame: before cataract phacoemulsification
|
The anterior aqueous humor was extracted before cataract phacoemulsification in the combined operation group.
The aqueous humor concentrations of VEGF, IL-2, IL-4, and TNF were checked by RT-PCR and ELISA analysis.
|
before cataract phacoemulsification
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Zijian Yang, Dr, Department of Ophthalmology, Ruijin Hospital north, Affiliated Medical School, Shanghai Jiaotong University
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Eye Diseases
- Endocrine System Diseases
- Diabetic Angiopathies
- Diabetes Complications
- Diabetes Mellitus
- Lens Diseases
- Retinal Diseases
- Diabetic Retinopathy
- Cataract
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Ranibizumab
Other Study ID Numbers
Other Study ID Numbers
- RuijinH202201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.